Skip to content

    Solara Active

    SOLARA
    Healthcare·10 Feb 2026
    Management Summary

    Solara Active Pharma Sciences reported a challenging Q3 FY26, primarily due to significant headwinds in its legacy ibuprofen business, which impacted overall gross margins to 47%. Despite this, the non-ibuprofen growth API segment demonstrated strong profitability with 56% gross margins and 25% EBITDA. The company is actively evaluating strategic options for the ibuprofen business and aims to revive its mothballed Vizag plant for multipurpose API production, while also reducing debt by INR 146 crores and targeting sub INR 500 crores by May '26.

    Highlights

    5

    • Non-ibuprofen growth API business demonstrated strong profitability with 56% gross margin and 25% EBITDA, above industry range.

    • Revenue grew 10% quarter-on-quarter to INR 346 crores, and approximately 15% year-on-year.

    • Debt was reduced by INR 146 crores, including INR 113 crores from rights issue and INR 33 crores from operational cash flows.

    • Developed markets continue to be a strong contributor, accounting for 75% of overall sales.

    • Strategic R&D focus shifted towards high-potent APIs and conversion of Vizag plant to a multipurpose facility, with commercial production targeted within 5-6 months.

    Concerns

    4

    • The legacy ibuprofen business remains a significant drag, facing headwinds in pricing and capacity utilization, impacting overall profitability.

    • Gross margins for the quarter were 47%, a decline of 386 basis points quarter-on-quarter, making it one of the lowest reported.

    • A one-time adverse impact of INR 6.7 crores (INR 67 million) was incurred due to increased gratuity and leave encashment liability from the new labor wage code.

    • The Vizag facility is currently mothballed, and the Pondicherry facility operates at low utilization (3,000 tons out of 12,000 tons total capacity).

    Key financials

    Single quarter

    04 metrics
    1. 01Revenue₹346 Cr+15%YoY
    2. 02Gross Margin47%-3.9%QoQ
    3. 03EBITDA₹37 Cr+6%QoQ
    4. 04Exceptional Item (Labor Code)67 Mn

    Segment breakdown

    Non-Ibuprofen / Growth API Business
    56% Gross Margin25% EBITDA Margin
    List

    Capital allocation

    1
    high confidence
    CategoryHeadline
    Debt

    Debt disclosed

    Guidance & targets

    5
    CategoryTargetPriority
    Debt
    Debt Reduction
    Sub INR 500 crores
    		High
    Capacity
    Vizag Plant Commercial Production
    Operational
    		High
    Product Launch
    OneSource CDMO Product Launch
    Launch
    		High
    Other
    Ibuprofen Business Analysis Results
    Results of analysis
    		High
    Other
    Ibuprofen Business Strategic Decisions
    Clear view/decisions
    		High

    Ibuprofen Business Strategic Decisions & Financial Impact

    Q4 FY26 results (end of April)
    CurrentUnder strategic review, results expected Q4 FY26.
    TargetClear decisions on ibuprofen business, including potential cost reductions or strategic resets, and quantified financial impact.

    Why it matters

    The resolution of the ibuprofen business is central to improving overall company profitability and future strategic direction.

    We expect to have this -- the results of an anlysis to be part of our Q4 results.

    How to verify

    guidance_and_targets[metric='Ibuprofen Business Strategic Decisions']

    Risks & concerns

    3
    RiskSeverity

    Headwinds in ibuprofen business (pricing, capacity utilization, dated processes)

    Ibuprofen business is a significant drag on overall profitability due to intense competition, excess capacity, and dated processes, leading to under-recovery. — Management acknowledged

    high

    One-time financial impact from new labor wage code

    INR 6.7 crores (or INR 67 million) adverse impact due to increased gratuity and leave encashment liability effective November 21, 2025. — Management acknowledged

    medium

    Delay in corporate actions due to ibuprofen business re-evaluation

    All corporate actions, including previously announced intentions for Vizag, are being delayed until the strategic review of the ibuprofen business is complete. — Management acknowledged

    medium

    Q&A highlights

    6

    “Listen, we believe that any work that we deploy focuses on the best value creation for all our stakeholders. We ensure that our processes are robust. We have a very independent committee of the Board that reviews these kind of matters. It is not something that we are obliged to follow through if it doesn't create the necessary outcome for the benefit of the organization.”

    Addresses concerns about the independence and effectiveness of the strategic review for the struggling ibuprofen business.

    asked by Sajal Kapoor

    2 min read6 chapters

    Detailed Narrative

    01

    Ibuprofen Business Challenges and Strategic Review

    The company is facing significant headwinds in its legacy ibuprofen business, which has been a drag on overall performance. This segment, once a global leader, is now impacted by dated processes, intense generic competition, and excess capacity, leading to low utilization (3,000 tons out of 12,000 tons total capacity). Management has initiated a strategic review, seeking external advice, with results expected by Q4 FY26 and decisions by end of April.

    02

    Strong Performance of Non-Ibuprofen Growth API Segment

    In contrast to the ibuprofen business, the non-ibuprofen growth API segment is performing robustly. This segment, which the company has invested in over the last 16-17 months, reported a gross margin of 56% and an EBITDA margin of 25%, placing it at the higher end of the industry range for API businesses. This growth is driven by complex, niche products from four FDA-approved plants, and contributes 75% of overall sales from developed markets.

    03

    Q3 FY26 Financial Overview

    For Q3 FY26, Solara reported a revenue of INR 346 crores, marking a 10% sequential growth and approximately 15% year-on-year growth. However, gross margins declined by 386 basis points quarter-on-quarter to 47%, primarily due to the ibuprofen business. EBITDA for the quarter stood at INR 37 crores, reflecting a marginal 6% Q-o-Q growth, also impacted by the lower gross margins.

    04

    Debt Reduction and Balance Sheet Strengthening

    The company has made progress in strengthening its balance sheet, reducing debt by INR 146 crores, representing a 19% reduction. This was achieved through INR 113 crores from rights issue proceeds and INR 33 crores from operational cash flows. Management has a clear line of sight to further reduce debt to below INR 500 crores by May 2026, post the receipt of final call money.

    05

    Vizag Plant Conversion and R&D Focus

    The mothballed Vizag facility, which previously produced ibuprofen, is planned for conversion into a multipurpose and high-potent API plant. This strategic shift, supported by renewed R&D efforts and investments in new talent, aims to bring the plant back into commercial production within the next 5-6 months. This initiative is part of a broader R&D rethink to build a sustainable, scalable, and high-margin portfolio.

    06

    One-Time Impact from New Labor Code

    The company incurred a one-time📎 adverse financial impact of INR 6.7 crores (or INR 67 million) in Q3 FY26. This was due to increased liability for gratuity and leave encashment, resulting from the new labor wage code that became effective on November 21, 2025.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.